S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:HSDT

Helius Medical Technologies - HSDT Competitors

$0.53
-0.02 (-3.61%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.50
$0.57
50-Day Range
$0.48
$2.02
52-Week Range
$0.45
$15.68
Volume
6.69 million shs
Average Volume
1.23 million shs
Market Capitalization
$2.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

HSDT vs. NUWE, KPRX, SPRC, VLON, THMO, AGRX, SXTC, GNCA, CGIX, and FWBI

Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include Nuwellis (NUWE), Kiora Pharmaceuticals (KPRX), SciSparc (SPRC), Vallon Pharmaceuticals (VLON), ThermoGenesis (THMO), Agile Therapeutics (AGRX), China SXT Pharmaceuticals (SXTC), Genocea Biosciences (GNCA), Cancer Genetics (CGIX), and First Wave BioPharma (FWBI). These companies are all part of the "medical" sector.

Helius Medical Technologies vs.

Helius Medical Technologies (NASDAQ:HSDT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

Helius Medical Technologies currently has a consensus target price of $20.00, suggesting a potential upside of 3,643.22%. Nuwellis has a consensus target price of $7.50, suggesting a potential upside of 983.35%. Given Helius Medical Technologies' higher possible upside, research analysts clearly believe Helius Medical Technologies is more favorable than Nuwellis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helius Medical Technologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Nuwellis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Helius Medical Technologies has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Nuwellis has a net margin of -240.83% compared to Helius Medical Technologies' net margin of -3,043.95%. Nuwellis' return on equity of -77.16% beat Helius Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Helius Medical Technologies -3,043.95% -240.53% -180.70%
Nuwellis -240.83% -77.16% -65.30%

Nuwellis received 2 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. However, 54.84% of users gave Helius Medical Technologies an outperform vote while only 52.78% of users gave Nuwellis an outperform vote.

CompanyUnderperformOutperform
Helius Medical TechnologiesOutperform Votes
17
54.84%
Underperform Votes
14
45.16%
NuwellisOutperform Votes
19
52.78%
Underperform Votes
17
47.22%

Helius Medical Technologies has higher earnings, but lower revenue than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helius Medical Technologies$520 thousand3.90-$18.13 million-$7.05-0.08
Nuwellis$7.92 million0.92-$19.58 million-$1.99-0.35

29.7% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 18.2% of Nuwellis shares are held by institutional investors. 11.2% of Helius Medical Technologies shares are held by insiders. Comparatively, 0.9% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Helius Medical Technologies had 4 more articles in the media than Nuwellis. MarketBeat recorded 11 mentions for Helius Medical Technologies and 7 mentions for Nuwellis. Nuwellis' average media sentiment score of 1.47 beat Helius Medical Technologies' score of 0.98 indicating that Nuwellis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helius Medical Technologies
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuwellis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Nuwellis beats Helius Medical Technologies on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSDT vs. The Competition

MetricHelius Medical TechnologiesElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$2.03M$3.74B$4.41B$6.38B
Dividend YieldN/A1.44%7.26%3.17%
P/E Ratio-0.0812.73123.5518.51
Price / Sales3.9039.272,950.75128.88
Price / CashN/A30.7722.8929.84
Price / Book0.183.776.466.21
Net Income-$18.13M$133.75M$166.90M$239.70M
7 Day Performance9.11%6.84%4.70%4.54%
1 Month Performance-50.07%15.15%10.80%12.20%
1 Year Performance-96.28%-27.94%-27.19%-20.33%

Helius Medical Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUWE
Nuwellis
2.1621 of 5 stars
$0.67
+1.5%
$7.50
+1,027.2%
-83.7%$7.01M$7.92M-0.2970Positive News
KPRX
Kiora Pharmaceuticals
2.5321 of 5 stars
$0.16
flat
$1.75
+1,029.0%
N/A$2.03M$10,000.00-0.0914Analyst Downgrade
High Trading Volume
SPRC
SciSparc
1.1469 of 5 stars
$1.24
-0.8%
N/AN/A$1.29M$1.99M0.002News Coverage
Positive News
Gap Up
VLON
Vallon Pharmaceuticals
2.0463 of 5 stars
$0.40
+8.2%
$12.00
+2,937.2%
-89.1%$2.69M$100,000.00-0.323Gap Up
THMO
ThermoGenesis
2.7113 of 5 stars
$0.22
flat
$6.00
+2,627.3%
-87.8%$2.82M$9.29M-0.2439
AGRX
Agile Therapeutics
2.3737 of 5 stars
$0.63
-5.9%
$130.00
+20,388.6%
-98.7%$2.88M$4.10M-0.0228Earnings Report
Analyst Upgrade
Gap Down
SXTC
China SXT Pharmaceuticals
0 of 5 stars
$1.52
-5.0%
N/A-93.1%$3.09M$2.60M0.0096
GNCA
Genocea Biosciences
1.559 of 5 stars
$0.01
flat
$3.00
+27,172.7%
-99.4%$646,000.00$1.64M-0.0274
CGIX
Cancer Genetics
0 of 5 stars
$0.79
-1.2%
N/AN/A$3.24MN/A0.00N/A
FWBI
First Wave BioPharma
2.2019 of 5 stars
$0.16
+6.8%
$8.50
+5,296.8%
N/A$3.27MN/A0.0017Positive News
This page (NASDAQ:HSDT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.